



## VALUE OUR HEALTH

### An Introduction to the Institute for Clinical and Economic Review (ICER) and Their Implications for New Sickle Cell Disease Treatments: A Primer on the Issues

**Date:** January 16, 2020

**Time:** 2:00-3:00 p.m. ET

We welcome interested stakeholders, patients, advocates, caregivers and families to join a webinar providing information about the metric used to assess the value of health care treatments called the quality-adjusted life year or “QALY” as well as the primary organization conducting QALY-based value assessments called the Institute for Clinical Economic Review (ICER). Because ICER will assess the value of new sickle cell disease treatments in March, 2020, it is important for all stakeholders to understand QALYs, ICER and how those value assessments may be used by public and private payers in their decisions related to drug coverage and formularies.

We are excited to have Sara van Geertruyden with the Partnership to Improve Patient Care (PIPC) join us to present information about QALYs and ICER. Other stakeholders will provide specific information about their experience with ICER so far as they determine the scope of their upcoming report, the sickle cell disease treatments under review, and an overview of treatments in the development pipeline.

Please RSVP to [dgleason@pipcpatients.org](mailto:dgleason@pipcpatients.org)